ACTBL2 and ovarian carcinoma: As our results confirmed a significant decrease in proliferation and migration of ovarian cancer cells upon specific downregulation of NFAT5 and ACTBL2, the irreversible blockade of CPT1 provided by Etomoxir might display a new and more precise antiproliferative approach in oncology, assumptively diminishing the therapy-limiting cytotoxicity upon systemic treatment.